Alnylam Gets EU Approval for AMVUTTRA in ATTR Amyloidosis
First and Only RNAi Therapeutic Approved by the European Commission for the Treatment of Wild-Type or Hereditary ATTR Amyloidosis with Cardiomyopathy – Novel RNAi Mechanism...
Tag : drug development challenges
ImmunoPrecise AI Platform LENSai™ Aligns with FDA’s New Policy
ImmunoPrecise Antibodies Ltd. (IPA) (NASDAQ: IPA) a leader in AI-driven biotherapeutics, today announced its strong support for the U.S. Food and Drug Administration’s (FDA) recent decision to...